Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies

Simone Ferrero, Umberto Leone Roberti Maggiore, Carolina Scala, Martina Di Luca, Pier Luigi Venturini, Valentino Remorgida
Archives of gynecology and obstetrics · 2012 · vol. 287(3) , pp. 447–453 · doi:10.1007/s00404-012-2581-2 · PMID:23053314 · W2072547957
article OA: closed CC0 ⤵ 46 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06+body, 2026-06-08 ⓘ

Hormonal therapies over 12 months significantly reduced rectovaginal endometriotic nodule volume in most patients, with volume decreasing at 6 and 12 months compared to baseline.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-08 ⓘ

This prospective, non-randomized, self-controlled clinical trial evaluated changes in the volume of rectovaginal endometriotic nodules infiltrating the rectum in women over 12 months of hormonal therapy, using virtual organ computer-aided analysis (VOCAL) at baseline and after 6 and 12 months. Participants received one of several regimens (norethisterone acetate, triptorelin, tibolone, norethisterone acetate plus letrozole, desogestrel, or a sequential oral contraceptive pill), and 83 women completed the study. Compared with baseline, nodule volume decreased at 6 and 12 months (p < 0.001 for both), with decreases observed in most women (68/83; 73.9%) but increases in a minority (11/83; 12.0%). The paper’s limitation is its non-randomized design and self-controlled structure rather than randomized parallel comparisons. This paper is centrally about endometriosis—specifically, how 12-month hormonal therapies change the size of rectovaginal endometriotic nodules infiltrating the rectum.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Rectal Diseases Vaginal Diseases Adult Aromatase Inhibitors Aromatase Inhibitors Calcium Calcium Cholecalciferol Cholecalciferol Contraceptives, Oral, Sequential Contraceptives, Oral, Sequential Contraceptives, Oral, Synthetic Contraceptives, Oral, Synthetic Desogestrel Desogestrel Endometriosis Endometriosis Estrogen Receptor Modulators Estrogen Receptor Modulators

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (33)

Cited by (46)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:15:58.344756+00:00
License: CC0 · commercial use OK